

Abstract Title: Updated results of the ASPEN trial from a cohort of patients with wild-type *MYD88* Waldenström macroglobulinemia (*MYD88*^{WT} WM)

Authors: Meletios Dimopoulos, MD¹; Ramon Garcia Sanz, MD, PhD²; Hui-Peng Lee, MBChB, FRACP, FRCPA³; Marek Trnety, MD, CSc⁴; Marzia Varettoni, MD⁵; Stephen Opat, MBBS, FRACP, FRCPA^{6,7}; Shirley D'Sa, MD, MRCP, FRCPath⁸; Roger G. Owen, MD⁹; Gavin Cull, MB, BS, FRACP, FRCPA^{10,11}; Stephen Mulligan, MBBS, PhD, FRACP, FRCPA¹²; Jaroslaw Czyz, MD, PhD^{13,14}; Jorge Castillo, MD^{15,16}; Marina Motta, MD¹⁷; Tanya Siddiqi, MD¹⁸; Mercedes Gironella Mesa, MD¹⁹; Miquel Granell Gorrochategui, MD²⁰; Dipti Talaulikar, PhD, FRACP, FRCPA, MBBS²¹; Pier Luigi Zinzani, MD, PhD²²; Elham Askari, MD²³; Sebastian Grosicki, MD, PhD²⁴; Albert Oriol, MD²⁵; Janusz Kloczko, MD²⁶; Alessandra Tedeschi, MD²⁷; Christian Buske, MD²⁸; Veronique Leblond, MD²⁹; Wai Y. Chan, PhD³⁰; Jingjing Schneider, PhD³⁰; Aileen Cohen, MD, PhD³⁰; Jane Huang, MD³⁰; and Constantine S. Tam, MBBS, MD, FRACP, FRCPA^{31,32,33,34}

Affiliations: ¹National and Kapodistrian University of Athens, Athens, Greece; ²Hospital Universitario de Salamanca, Salamanca, Spain; ³Flinders Medical Centre, Adelaide, South Australia, Australia; ⁴Všeobecná fakultní nemocnice v Praze, Prague, Czech Republic; ⁵Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; ⁶Monash Health, Clayton, Victoria, Australia; ⁷Monash University, Clayton, Victoria, Australia; ⁸University College London Hospital Foundation Trust, London, United Kingdom; ⁹St James University Hospital, Leeds, United Kingdom; ¹⁰Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; ¹¹University of Western Australia, Perth, Western Australia, Australia; ¹²Royal North Shore Hospital, Sydney, New South Wales, Australia; ¹³Szpital Uniwersytecki nr 2 im dr. Jana Bizuela, Kujawsko-pomorskie, Bydgoszcz, Poland; ¹⁴Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland; ¹⁵Dana-Farber Cancer Institute, Boston, MA, USA; ¹⁶Harvard Medical School, Boston, MA, USA; ¹⁷AO Spedali Civili di Brescia, Lombardia, Italy; ¹⁸City of Hope National Medical Center, Duarte, CA, USA; ¹⁹Hospital Universitario Vall d'Hebrón, Barcelona, Spain; ²⁰Hospital de La Santa Creu i Sant Pau, Barcelona, Spain; ²¹Australian National University, Canberra, ACT, Australia; ²²Institute of Hematology "Seràgnoli" University of Bologna, Bologna, Italy; ²³Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; ²⁴Department of Hematology and Cancer Prevention, Health Sciences Faculty, Medical University of Silesia, Katowice, Poland; ²⁵Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; ²⁶Uniwersytecki Szpital Kliniczny w Białymstoku, Podlaskie, Poland; ²⁷ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; ²⁸CCC Ulm - Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany; ²⁹Sorbonne University, Pitié Salpêtrière Hospital, Paris, France; ³⁰BeiGene USA, Inc., San Mateo, CA, USA; ³¹Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; ³²St Vincent's Hospital, Fitzroy, Victoria, Australia; ³³University of Melbourne, Parkville, Victoria, Australia; and ³⁴Royal Melbourne Hospital, Parkville, Victoria, Australia

Background: Inhibitors of Bruton's tyrosine kinase (BTK) have shown significant activity in patients with *MYD88* mutation–positive (*MYD88*^{mut+}) WM. However, lower response rates and shorter progression-free survival have been reported in patients with WM who lack such mutations (*MYD88*^{WT}).

Aim/Objective: The ASPEN trial (NCT03053440) evaluated zanubrutinib, a potent and selective BTK inhibitor, in patients with *MYD88* mutation (*MYD88*^{mut+}) and wild-type *MYD88* (*MYD88*^{WT}) WM. The objective of this abstract is to detail the safety and efficacy of zanubrutinib in patients with *MYD88*^{WT} WM.

Methods: In the ASPEN trial, *MYD88* gene mutations were assessed at study entry by a central laboratory (NeoGenomics). Based on these results, patients were assigned to cohort

1 (*MYD88*^{mut+}) or cohort 2 (*MYD88*^{WT} or unknown mutation status). Patients received zanubrutinib 160 mg twice daily until disease progression.

Results: In total, 28 patients were enrolled in cohort 2, of which 26 were centrally confirmed as *MYD88*^{WT}. Median age of patients was 72 years; five patients were treatment-naïve and 23 patients had relapsed/refractory (≥ 1 prior therapy) WM. Most patients had intermediate-risk (39.3%) or high-risk (42.9%) disease, as defined by the International Prognostic Scoring System for WM. At a median follow-up of 17.9 months, two patients discontinued zanubrutinib due to adverse events (AEs), and six experienced disease progression; there were no cases of disease transformation. In 26 confirmed *MYD88*^{WT} patients, the overall response rate by independent review (IRC) was 80.8%, with a major response rate of 50.0%, including a very good partial response rate of 26.9%. The progression-free survival event-free rate at 12 months was 72.4%. The most frequently reported AEs were diarrhea, anemia, contusion, pyrexia, and upper respiratory tract infection. Major hemorrhage was reported in two patients, and atrial fibrillation was reported in one patient. There were no fatal AEs.

Conclusions: Zanubrutinib showed clinically meaningful antitumor activity, including achieving major responses and durability of responses, and was considered well tolerated with a low discontinuation rate due to AEs in patients with *MYD88*^{WT} WM.